Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: AstraZeneca 15.384, Structure Therapeutics 0.
AstraZeneca vs Structure Therapeutics: Revenue Comparison
AstraZeneca (AZN) and Structure Therapeutics (GPCR) are peers in GLP-1. AstraZeneca reported revenue of $15.4B as of Q2 2026, compared with $0 for Structure Therapeutics. AstraZeneca leads on revenue.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, AstraZeneca, Structure Therapeutics.| Metric | AstraZeneca | Structure Therapeutics |
|---|---|---|
| Market Cap | - | - |
| Revenue | $15.38B | $0 |
| Cost of Revenue | $2.52B | $0 |
| Gross Profit | $12.86B | $0 |
| Operating Income | $3.16B | $-119.00M |
| Net Income | $2.51B | $-106.00M |
| R&D Expense | $4.05B | $100.00M |
| Earnings Per Share | $1.59 | -$1.47 |
| Gross Margin | 83.6% | - |
| Operating Margin | 20.6% | - |
| Net Profit Margin | 16.3% | - |
| Free Cash Flow | $2.13B | $-120.00M |
| Cumulative Free Cash Flow | $121.22B | $-589.00M |
| Operating Cash Flow | $2.89B | $-120.00M |
| Cash & Equivalents | $4.89B | $273.00M |